Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI Study of XZP-3621 with Itraconazole, Rifampin, or Esomeprazole in Healthy Subjects
NCT05586568Phase 1Unknown
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dirozalkib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Area under the concentration versus time curve up to 1 month and Maximum serum concentration up to 1 week. Status: unknown.
02
Drugs
dirozalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05586568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586568.